Clinical Trials Logo
  1. Home
  2. Biliary Tract Cancer
  3. NCT04731220
  4. Details
NCT04731220 Clinical Trial

A Questionnaire Survey for Biliary Tract Cancers

Biliary Tract Cancer Clinical Trial

Official title:
A Questionnaire Survey Study for Establishment of Surveillance and Prevention Through the Analysis of Epidemiologic Risk Factors in Patients With Biliary Tract Cancers

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT04731220
Other study ID # KNUCH 2020-04-045
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date July 14, 2020
Est. completion date December 31, 2025

Study information
Verified date January 2021
Source Kyungpook National University Chilgok Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is: - To evaluate risk factors for cancers of the biliary tract by registering new patients and their counterparts in a multi-center program - Development of programs by creating a multi-center biliary tract cancer registration system

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 12000
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Study population : - Newly diagnosis of biliary tract cancers - Pathological or Radiological or other clinical diagnosis of biliary tract cancers - Informed consent - Control : - with no previous cancer diagnosis - Informed consent Exclusion Criteria: - Previous diagnosis of bile duct cancer with resection operation, endoscopic resection, chemotherapy or radiation therapy - Prior diagnosis of other cancer in 5 years or ongoing cancer treatment - Patients' refusal

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Kyungpook National University Chilgok Hospital Daegu

Sponsors (4)
Lead Sponsor Collaborator
Kyungpook National University Chilgok Hospital Kyungpook National University Hospital, Pusan National University Hospital, Pusan National University Yangsan Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number and percentage of cases and controls who complete each part of the study Information is obtained by a questionnaire, laboratory findings, image data, physiological parameter. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Withdrawn NCT03110510 - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00380588 - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase 2
Terminated NCT00090025 - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Phase 3
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT05998447 - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer Phase 2
Recruiting NCT03718897 - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting NCT05056116 - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer N/A
Recruiting NCT04692051 - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Terminated NCT04057365 - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Recruiting NCT04584996 - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed NCT02579616 - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Phase 2
Recruiting NCT05052099 - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT01494363 - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Phase 2
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Terminated NCT00630890 - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition